Consultation hotline:
ZTR is a Potent Oral Kinase CDK9/2/5/7 inhibitor that readily crosses the Blood Brain Barrier(BBB)。 ZTR demonstrates strong efficacy in recurrent High-grade glioma (rHGG) and Diffuse intrinsic pontine glioma (DIPG). In recent days, we are in preparing process of registration two Phase 2 clinicaltrails of the above indications in US.
  • CDK9 inhibition MOA
    • ZTR depletes MYC levels,lowering glucose metabolism to stunt tumor formation and growth
    • oMitigate the effect of mutant IDH on the oncogenic process
  • Indications
    recurrent High-grade glioma (rHGG)
    • Most common and aggressive forms of malignant brain tumor
    • Incidence of ~45K patients in the US, EU, and JPN
    • Specifically Supportive IDH Mutant as an Enriched Population
  • Diffuse intrinsic pontine glioma (DIPG)
    • Paediatric brainstem glioma,a leading cause of childhood cancer-related deaths.
    • ~1650 pts in the US and EU1-3,age of onset 5-7 years old
    • Inoperable and TMZ-resistant, no treatments beyond radiation
Copyright 2015 Beijing zhikangbo Medical Oncology Research Co., Ltd 京ICP备15041820号